We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Multimillion Dollar Investment Launches Drug Development Research Startup

By LabMedica International staff writers
Posted on 28 Jun 2015
Print article
A global healthcare company with research and development interests in the area of pharmaceuticals, vaccines, and consumer healthcare will be financing an independent startup to promote drug development through advances in the understanding of gene function and control.

The biopharmaceutical company GlaxoSmithKline (London, United Kingdom) will be investing 95 million USD to launch the startup Altius Institute for Biomedical Sciences. Altius will be located in Seattle, WA, USA. The agreement is for 10 years of collaboration during which GlaxoSmithKline will have first rights to option inventions and products developed by Altius and to invest in commercialization of its discoveries via spinout companies. Additional funding from GlaxoSmithKline will be provided as necessary to tie technologies and discoveries made by Altius to a wide range of drug discovery and development projects.

“Dramatic breakthroughs in understanding how the human genome functions are still in their infancy in terms of how they can be applied to drug discovery, but we can see their potential to transform the process,” said Lon Cardon, senior vice president of alternative discovery and development at GlaxoSmithKline. “This is not an incremental change. We are aiming for transformative outcomes that could improve our ability to bring innovative and more effective new medicines to patients.”

Altius Institute for Biomedical Sciences is to be headed by Dr. John Stamatoyannopoulos, professor of genome sciences at the University of Washington (Seattle, USA). “With this visionary investment, GlaxoSmithKline is gaining a front-line view into the revolution now underway in understanding how cells function,” said Dr. Stamatoyannopoulos. “Innovative technologies are needed to gain a deeper understanding of how cells’ "operating systems" work.”

Related Links:

GlaxoSmithKline
University of Washington School of Medicine



New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Progesterone Serum Assay
Progesterone ELISA Kit
New
Silver Member
Rubella Infection ELISA
ReQuest RUBELLA IgM ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.